Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07356050 · ClinicalTrials.gov registry record
Verifying Antibodies After Live Immunization Delivery (VALID): A Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease
A clinical trial of Sickle Cell Disease and Sickle Cell Anemia, sponsored by Children's Hospital Medical Center, Cincinnati.
- Recruiting
- Registry status
- 130
- Enrollment target
- 3
- Study locations
NCT07356050: Recruiting study of Sickle Cell Disease and Sickle Cell Anemia, sponsored by Children's Hospital Medical Center, Cincinnati.
NCT07356050 is a study of Sickle Cell Disease and Sickle Cell Anemia that is actively recruiting participants, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 130 participants, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (55% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07356050, a study of Sickle Cell Disease and Sickle Cell Anemia, is actively recruiting participants, sponsored by Children's Hospital Medical Center, Cincinnati.
- RECRUITING
- Registry status
- 130 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this study is to learn if infants with sickle cell disease (SCD) develop adequate protection after measles vaccines. (not looking at any prolonged duration)
Primary Outcome
Sample analysis of 126 participants 8-weeks post complete measles vaccination.
Conditions Studied
Study Locations (3)
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Ghana
- Korle Bu Teaching Hospital - Accra
Other
- Bugando Medical Centre - Mwanza
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2025-03-13 |
| Est. Completion | 2028-12-31 |
What NCT07356050 shows while recruiting
NCT07356050 is an observational study that tracks outcomes without assigning an intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (55% lower).
The record links to 3 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 0 interventions.
NCT07356050 reports a single indexed study location in Ohio, Ghana, Other.
Frequently Asked Questions
What is clinical trial NCT07356050 about?
NCT07356050 is a clinical study titled "Verifying Antibodies After Live Immunization Delivery (VALID): A Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease". The goal of this study is to learn if infants with sickle cell disease (SCD) develop adequate protection after measles vaccines. (not looking at any prolonged duration)
What is the current status of trial NCT07356050?
This trial is currently recruiting. The enrollment target is 130 participants. The study started on 2025-03-13. Estimated completion is 2028-12-31.
What conditions does trial NCT07356050 study?
This clinical trial studies the following conditions: Sickle Cell Disease, Sickle Cell Anemia, Measles Vaccination.
Who is sponsoring clinical trial NCT07356050?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07356050 being conducted?
This trial has 3 study locations across Ohio, Ghana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07356050's enrollment target sits among peer trials
130 48th of 213 higher than 165 of 213 other Sickle Cell Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Early Life Exposures Among Children With Sickle Cell Disease
RECRUITING · NA
-
Exercise in Child Health
RECRUITING · NA
-
Sickle Cell Children's Exercise Study (SuCCESs)
RECRUITING · NA
-
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
RECRUITING · Phase 1
-
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492036 · 130 participants
Long-Term Follow-Up of Recipient of Gene Transfer Research
- NCT01631617 · 130 participants · Phase 2
Effects of Treatments on Atopic Dermatitis
- NCT02368041 · 130 participants
Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure
- NCT02604277 · 130 participants · NA
Suicidal Behavior in Patients Diagnosed With Bipolar Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI